11 completed, 2 terminated, 2 unknown. 15 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 11, Terminated 2, Unknown 2 |
Follow Acarbose: new trials by email Literature Review of Acarbose trials Research Report on Acarbose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes Metformin plus pioglitazone, Acarbose - Type 2 Diabetes, Blood Glucose Fluctuation | Phase 3 | Unknown | Nanjing First Hospital, Nanjing Medical University | 50 | 2022-04-10 | 2022-11-29 |
| Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus. Acarbose, Prandial insulin - Gestational Diabetes Mellitus in Pregnancy | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 341 | 2018-07-04 | 2024-07-03 |
| Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients Acarbose, Metformin, Placebo - Diabetes Mellitus, Type 2 | Phase 3 | Completed | Bayer | 287 | 2018-03-05 | 2020-08-05 |
| Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes Saxagliptin, Acarbose - Type 2 Diabetes | Phase 3 | Completed | Zilin Sun | 22 | 2015-04-03 | 2018-07-06 |
| A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus ASP1941, acarbose, Placebo - Type II Diabetes Mellitus | Phase 3 | Terminated | Astellas Pharma Inc | 46 | 2012-04-23 | 2024-11-12 |
| Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130) Sitagliptin phosphate, Comparator: Placebo, Acarbose - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 380 | 2011-01-25 | 2018-08-16 |
| A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus Acarbose, Metformin/Acarbose - The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg, Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in | Phase 3 | Unknown | Lotus Pharmaceutical | 220 | 2010-11-01 | 2010-11-22 |
| A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients ipragliflozin, alpha glucosidase inhibitor - Type 2 Diabetes Mellitus | Phase 3 | Completed | Astellas Pharma Inc | 113 | 2010-10-21 | 2025-05-30 |
| Vildagliptin and Endothelium-dependent Vasodilatation vildagliptin + acarbose, acarbose + vildagliptin - Type 2 Diabetes, Endothelial Dysfunction | Phase 3 | Completed | Radboud University Medical Center | 16 | 2010-01-01 | 2010-11-05 |
| Effects of Acarbose on Endothelial Function After a Mixed Meal in Newly Diagnosed Type 2 Diabetes acarbose, placebo - Type 2 Diabetes | Phase 3 | Completed | Technische Universität Dresden | 2006-07-01 | 2013-03-01 | |
| Acarbose and Secondary Prevention After Coronary Stenting Acarbose - Glucose Metabolism Disorders, Coronary Artery Disease | Phase 3 | Completed | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 300 | 2005-05-01 | 2009-06-25 |
| AI(I)DA Acarbose and the Subclinical Inflammation acarbose - Type 2 Diabetes Mellitus, Subclinical Inflammation | Phase 3 | Completed | GWT-TUD GmbH | 104 | 2005-01-01 | 2008-04-11 |
| Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care Acarbose (Glucobay, BAYG5421), Placebo - Diabetes Mellitus | Phase 3 | Completed | Bayer | 204 | 2000-08-01 | 2010-12-28 |
| Action to Control Cardiovascular Risk in Diabetes (ACCORD) Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin - Atherosclerosis, Cardiovascular Diseases | Phase 3 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 10251 | 1999-09-01 | 2016-11-22 |
| Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM Trial acarbose, placebo - Metabolic Syndrome | Phase 3 | Completed | GWT-TUD GmbH | 1429 | 2008-03-07 |
Diabetes Mellitus, Type 2 (11) · Diabetes Mellitus (5) · Atherosclerosis (1) · Cardiovascular Diseases (1) · Coronary Artery Disease (1) · Coronary Disease (1) · Glucose Intolerance (1) · Glucose Metabolism Disorders (1) · Glycosuria (1) · Hypercholesterolemia (1) · Hypertension (1) · Metabolic Diseases (1) · Metabolic Syndrome (1)
Astellas Pharma Inc (2) · Bayer (2) · GWT-TUD GmbH (2) · Assistance Publique - Hôpitaux de Paris (1) · Lotus Pharmaceutical (1) · Merck Sharp & Dohme LLC (1) · Nanjing First Hospital, Nanjing Medical University (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Radboud University Medical Center (1) · Technische Universität Dresden (1) · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan (1) · Zilin Sun (1)
China (3) · Germany (2) · Japan (2) · Taiwan (2) · Canada (1) · France (1) · Netherlands (1) · South Korea (1) · Spain (1) · United States (1)
C.J. Tack, MD, PhD, Prof. of Diabetology (1) · Denise Simons-Morton, MD, PhD (1) · Koichi Tamita, MD. (1) · Markolf Hanefeld, PhD (1) · Markolf Hanefeld, PhD, MD (1) · Minako Katayama, MD (1) · Robert Byington, PhD (1) · William Friedewald, MD (1) · Yutaka Furukawa, MD (1)
PMID 18539917, PMID 19156626, PMID 19898642, PMID 20061358, PMID 20061360, PMID 20215456, PMID 20228401, PMID 20228404, PMID 20427682, PMID 20571135, PMID 20587587, PMID 20594588, PMID 21366473, PMID 21663644, PMID 21958949, PMID 22019270, PMID 22049171, PMID 22179956, PMID 22374637, PMID 22432114, PMID 22450889, PMID 22515638, PMID 22619083, PMID 22646230, PMID 22723577, PMID 23033246, PMID 23238658, PMID 23412077, PMID 23990163, PMID 23993469, PMID 24170759, PMID 24296848, PMID 24485397, PMID 24493100, PMID 24595629, PMID 24779562, PMID 25088437, PMID 25127725, PMID 25159234, PMID 25172198, PMID 25193529, PMID 25229335, PMID 25267796, PMID 25652389, PMID 25666468, PMID 25887355, PMID 26261902, PMID 26459421, PMID 26464212, PMID 26476086
N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1), N01HC95183 (1), N01HC95184 (1)